ONUREG (AZACITIDINE)
ONUREG (AZACITIDINE) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: ONUREG; Generic name: AZACITIDINE; Drug class: Nucleoside Metabolic Inhibitor [EPC].
| Brand name | ONUREG |
|---|---|
| Generic name | AZACITIDINE |
| Drug class | Nucleoside Metabolic Inhibitor [EPC] |
| Manufacturer | Celgene Corporation |
| Used for | 1 INDICATIONS AND USAGE ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy. ONUREG is a nucleoside metabolic inhibitor indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy ( 1 ). |
| Dosage | 2 DOSAGE AND ADMINISTRATION • Do not substitute ONUREG for intravenous or subcutaneous azacitidine. The indications and dosing regimen for ONUREG differ from that of intravenous or subcutaneous azacitidine ( 2.1 , 5.1 ). • Administer ONUREG 300 mg orally once daily on Days 1 through 14 of each 28-day cycle ( 2.2 ). • Administer an antiemetic before each dose for at least the first 2 cycles ( 2.2 ). 2.1 Important Administration Information Do not substitute ONUREG for intravenous or subcutaneous |
| Active ingredient(s) | AZACITIDINE |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0e95e33f-8aba-4f19-b332-2416580d358b |